Clinical trials
Non-alcoholic Fatty Liver Disease trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 9 |
| 2018 | 1 |
| 2019 | 6 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Recruiting | 8 |
| Unknown status | 8 |
| Terminated | 5 |
| Active, not recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Maastricht University Medical Center | 11 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 4 |
| Genfit | 3 |
| 89bio, Inc. | 2 |
| Boehringer Ingelheim | 2 |
| Inventiva Pharma | 2 |
| Leiden University Medical Center | 2 |
| Novartis Pharmaceuticals | 2 |
| Novo Nordisk A/S | 2 |
| Perspectum | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Non-alcoholic Fatty Liver Disease | 42 |
| Fibrosis | 8 |
| Obesity | 8 |
| Liver Diseases | 6 |
| Diabetes Mellitus, Type 2 | 5 |
| Fatty Liver | 4 |
| Cardiovascular Diseases | 3 |
| Digestive System Diseases | 3 |
| Hepatitis | 3 |
| Insulin Resistance | 3 |
Trials
Showing 76 to 42 of 42. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.